When will Beam Therapeutics submit a BLA for Risto-cel?

before November

1.23x

before October

6.29x

$5,567 vol6 markets

Biotech

FDA decision: Brepocitinib by Priovant Therapeutics (this year)

Yes

1.18x

No

4.31x

$2,049 vol1 market

Medicine

When will the FDA reclassify BPC-157 to Category 1?

Before November

1.97x

Before 2027

1.65x

$83,371 vol3 markets

Eli Lilly

Will the FDA approve retatrutide?

Before Jul 1, 2027

1.97x

Before Jan 1, 2028

1.09x

$30,594 vol5 markets

Biotech

FDA decision: Iberdomide by BMS/Celgene (this year)

Yes

1.08x

No

6.29x

$5,308 vol1 market

Medicine

When will Compass Pathways submit a NDA for COMP360 psilocybin?

before November

1.48x

before October

2.98x

$13,105 vol6 markets

Biotech

FDA decision: Ivonescimab by Summit Therapeutics (this year)

Yes

1.42x

No

2.66x

$3,841 vol1 market

Medicine

Will the FDA approve camizestrant for advanced breast cancer?

Before Jan 1, 2027

1.55x

Before Oct 1, 2026

2.59x

$10,094 vol3 markets

Medicine

When will the FDA approve Compass Pathways’ COMP360 Psilocybin?

Before Mar 1, 2027

1.62x

Before Jan 1, 2027

2.66x

$15,337 vol5 markets

Medicine

Will the FDA approve a cure for Type 1 diabetes before 2033?

Yes

2.66x

No

1.50x

$9,285 vol1 market

Medicine

When will the FDA approve Intellia Therapeutics’ lonvo-z?

Before October 2027

1.67x

Before July 2027

2.73x

$3,517 vol3 markets

Eli Lilly

Will the FDA approve VERVE-102?

Before 2030

1.70x

Before 2031

1.46x

$1,458 vol6 markets

Biotech

FDA decision: Venglustat by Sanofi (this year)

Yes

1.19x

No

4.13x

$446 vol1 market

Biotech

FDA decision: Saroglitazar by Zydus Therapeutics (this year)

Yes

1.34x

No

2.89x

$348 vol1 market

Biotech

FDA decision: Rusfertide by Protagonist Therapeutics (this year)

Yes

1.10x

No

5.90x

$1,605 vol1 market

Medicine

When will Intellia Therapeutics submit a BLA for Lonvo-z?

before October

1.93x

before November

1.44x

$6,257 vol6 markets

Biotech

FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (this year)

Yes

1.25x

No

3.29x

$468 vol1 market

Biotech

FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (this year)

Yes

1.34x

No

2.81x

$817 vol1 market

Biotech

FDA decision: bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) by Gilead Sciences (this year)

Yes

1.08x

No

6.29x

$658 vol1 market

Biotech

FDA decision: Bepirovirsen by GlaxoSmithKline (this year)

Yes

1.31x

No

2.98x

$236 vol1 market

Biotech

FDA decision: BBP-418 by Ml Bio Solutions Inc. (this year)

Yes

1.10x

No

5.90x

$642 vol1 market

Biotech

FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (this year)

Yes

1.25x

No

3.52x

$488 vol1 market

Medicine

Tech & Science

Medicine

When will Beam Therapeutics submit a BLA for Risto-cel?

FDA decision: Brepocitinib by Priovant Therapeutics (this year)

When will the FDA reclassify BPC-157 to Category 1?

Will the FDA approve retatrutide?

FDA decision: Iberdomide by BMS/Celgene (this year)

When will Compass Pathways submit a NDA for COMP360 psilocybin?

FDA decision: Ivonescimab by Summit Therapeutics (this year)

Will the FDA approve camizestrant for advanced breast cancer?

When will the FDA approve Compass Pathways’ COMP360 Psilocybin?

Will the FDA approve a cure for Type 1 diabetes before 2033?

When will the FDA approve Intellia Therapeutics’ lonvo-z?

Will the FDA approve VERVE-102?

FDA decision: Venglustat by Sanofi (this year)

FDA decision: Saroglitazar by Zydus Therapeutics (this year)

FDA decision: Rusfertide by Protagonist Therapeutics (this year)

When will Intellia Therapeutics submit a BLA for Lonvo-z?

FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (this year)

FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (this year)

FDA decision: bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) by Gilead Sciences (this year)

FDA decision: Bepirovirsen by GlaxoSmithKline (this year)

FDA decision: BBP-418 by Ml Bio Solutions Inc. (this year)

FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (this year)

When will Beam Therapeutics submit a BLA for Risto-cel?

FDA decision: Brepocitinib by Priovant Therapeutics (this year)

When will the FDA reclassify BPC-157 to Category 1?

Will the FDA approve retatrutide?

FDA decision: Iberdomide by BMS/Celgene (this year)

When will Compass Pathways submit a NDA for COMP360 psilocybin?

FDA decision: Ivonescimab by Summit Therapeutics (this year)

Will the FDA approve camizestrant for advanced breast cancer?

When will the FDA approve Compass Pathways’ COMP360 Psilocybin?

Will the FDA approve a cure for Type 1 diabetes before 2033?

When will the FDA approve Intellia Therapeutics’ lonvo-z?

Will the FDA approve VERVE-102?

FDA decision: Venglustat by Sanofi (this year)

FDA decision: Saroglitazar by Zydus Therapeutics (this year)

FDA decision: Rusfertide by Protagonist Therapeutics (this year)

When will Intellia Therapeutics submit a BLA for Lonvo-z?

FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (this year)

FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (this year)

FDA decision: bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) by Gilead Sciences (this year)

FDA decision: Bepirovirsen by GlaxoSmithKline (this year)

FDA decision: BBP-418 by Ml Bio Solutions Inc. (this year)

FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (this year)